Analysts' average 12-month price target for Veradermicsorporated is $160.
Get informed when a big investor buys or sells
+ Follow$97.75
3 analysts in the last 4 months
High: $182 | Low: $136
No recommendations in the last 4 months.
Veradermicsorporated (MANE) currently reports a target price of $160. Use the charts on this page to explore Veradermicsorporated's target price history and peer comparisons.
Analysts' average 12-month price target for Veradermicsorporated is $160, about 66.4% upside from the current share price of $97.75. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.
Start with the current target price of $160, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Veradermicsorporated, and consider following MANE for alerts when major investors trade the stock.
Veradermicsorporated is classified in the Healthcare sector. On target price, it currently shows $160. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MANE with unrelated industries.